Steven Chmura to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Steven Chmura has written about Drug Resistance, Neoplasm.
Connection Strength
0.247
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.149
-
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol. 2016 Jan; 126(2):309-16.
Score: 0.099